Stockscreener 앱 받기
2.10
3.67%
-0.08
전일 마감가:
$2.18
열려 있는:
$2.16
하루 거래량:
302.00K
Relative Volume:
0.44
시가총액:
$230.11M
수익:
-
순이익/손실:
$1.60M
주가수익비율:
70.00
EPS:
0.03
순현금흐름:
$-62.91M
1주 성능:
-5.41%
1개월 성능:
-7.49%
6개월 성능:
+6.60%
1년 성능:
-12.13%
1일 변동 폭
$2.10
$2.19
1주일 범위
$2.10
$2.34
52주 변동 폭
$1.35
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
CGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.10 | 230.11M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 개시 | Oppenheimer | Outperform |
| 2022-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-26 | 재개 | JMP Securities | Mkt Outperform |
| 2020-05-13 | 개시 | Stifel | Buy |
| 2020-05-07 | 개시 | SVB Leerink | Outperform |
| 2020-04-22 | 개시 | ROTH Capital | Buy |
| 2020-03-24 | 개시 | SunTrust | Buy |
| 2020-01-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-29 | 개시 | Oppenheimer | Outperform |
| 2016-02-01 | 재개 | Oppenheimer | Outperform |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2015-04-23 | 재개 | Jefferies | Buy |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-02-07 | 개시 | MLV & Co | Buy |
| 2009-12-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2009-07-29 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Compugen Ltd 주식(CGEN)의 최신 뉴스
Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement - TipRanks
Earnings Alert: Compugen Sets Date for Critical Year-End Financial Report & Strategic Update - StockTitan
Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) - Seeking Alpha
Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Time to Sell? - Defense World
Compugen Updates Filing Structure with Bristol Myers Squibb - TipRanks
Computational Biology Market to Generate $9.52 Billion in Revenues in 2025; Forecast to Reach $22.47 Billion by 2029Analysis of the Key Drivers, Top Segments, Regional Shifts, Leading Players & More - Yahoo Finance
Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
CGEN’s Q2 earnings predictions: What the experts say - US Post News
Compugen Ltd (NASDAQ: CGEN) Has Decreased By 14.22 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
JPMorgan Chase & Co. Has $122,000 Stock Holdings in Compugen Ltd. (NASDAQ:CGEN) - MarketBeat
Views of Wall Street’s Leading Experts on Compugen Ltd - SETE News
The Psychology of Compugen Ltd Inc. (CGEN) Price Performance: Understanding Market Sentiment - The InvestChronicle
Insider’s View: Deciphering Compugen Ltd (CGEN)’s Financial Health Through Ratios - The Dwinnex
Investing in Compugen Ltd (CGEN) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Major Cancer Immunotherapy Breakthrough Could Be Unveiled at Oppenheimer Conference - StockTitan
JPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen (NASDAQ:CGEN) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
CGENCompugen Ltd Latest Stock News & Market Updates - StockTitan
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - Simply Wall St
Compugen (NASDAQ:CGEN) Now Covered by Oppenheimer - Defense World
Compugen Ltd (NASDAQ: CGEN) Gains 3.14% In Early Trade; What Lies Ahead? - Stocks Register
Oppenheimer Initiates Coverage on Compugen (NASDAQ:CGEN) - MarketBeat
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential By Investing.com - Investing.com Australia
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential - Investing.com India
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - Marketscreener.com
Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 - StockTitan
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy - AOL
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks
Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada
Compugen Reports Strong Q3 2024 Results and Progress - TipRanks
Compugen: Q3 Earnings Snapshot - The Washington Post
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance
Compugen Ltd (CGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):